Core Viewpoint - Morgan Stanley increased its stake in China National Pharmaceutical Group (01099) by acquiring 347,233 shares at an average price of HKD 21.4135 per share, totaling approximately HKD 7.4355 million, resulting in a new holding of about 67.1203 million shares, representing a 5% ownership stake [1] Group 1 - Morgan Stanley's acquisition of shares indicates confidence in China National Pharmaceutical Group's future performance [1] - The average purchase price of HKD 21.4135 per share reflects the current market valuation of the company [1] - The total investment of approximately HKD 7.4355 million signifies a strategic move to increase ownership in the company [1]

Group 1: Fund Premium Risk Alerts - 27 funds have issued premium risk alerts, primarily focusing on overseas theme QDII products covering markets such as the US, Brazil, France, Germany, and Japan [1] - Notable funds include Guotai Asset Management's silver LOF and Southern Oil LOF, which have also released premium alerts [1] - Fund companies are advising investors to be cautious of high premium rates in secondary market transactions to avoid significant losses [1] Group 2: Sales Fee Regulation - Starting from February 24, 2026, new regulations will prohibit fund managers from charging subscription fees and sales service fees for direct sales [1] - Currently, two public fund managers, Xingquan Fund and Caitong Asset Management, have announced the waiver of subscription fees for direct sales [1] Group 3: Semiconductor Industry Insights - The global silicon wafer shipment volume is projected to reach 12.973 billion square inches in 2025, marking a 5.8% increase from the previous year [1] - Despite the growth in shipment volume driven by AI and HBM demand, wafer sales revenue is expected to decline by 1.2% to $11.4 billion due to lagging demand and price recovery [1] Group 4: Television Panel Price Trends - In February 2026, television panel prices have increased, with the highest price rise reaching $3 for certain sizes [2] - The demand for television panels remains stable, and manufacturers are adjusting production capacity during the Lunar New Year [2] Group 5: Solar Industry Inventory Trends - During the Lunar New Year, silicon wafer prices remained stable, but inventory levels have increased due to reduced orders [2] - Battery manufacturers are expected to resume operations post-holiday, potentially leading to improved inventory levels [2] Group 6: Camera Price Surge - Camera prices have surged significantly, with some models increasing by up to 10 times their original price [3] - The market for cameras is experiencing a price trend contrary to that of smartphones, with certain models being referred to as "electronic gold" by consumers [3] Group 7: Gold Product Price Increases - Chow Tai Fook is expected to raise prices for gold products by 15%-30% around mid-March, with some stores already receiving notifications [3] - A specific gold bracelet is projected to increase from 53,800 yuan to 71,800 yuan, reflecting a price rise of over 33% [3] Group 8: Novo Nordisk Stock Decline - Novo Nordisk's stock plummeted over 16% following disappointing clinical trial results for its new weight loss drug CagriSema, which showed a 23% weight loss compared to 25.5% for Eli Lilly's competitor [4] - This decline has erased all gains from the previous weight loss drug, semaglutide, and poses challenges for Novo Nordisk in a competitive market [4] Group 9: Corporate Name Changes - Several companies under Wahaha have changed their names to "Hongsheng," indicating a potential rebranding strategy [5] Group 10: Business Contracts and Financial Performance -韶能股份 has signed a significant business contract worth 22 million yuan for an independent energy storage project [6] - 风范股份 has won a procurement project from Southern Power Grid valued at approximately 184 million yuan, representing 5.7% of its audited revenue for 2024 [7] - 恒誉环保 reported a 106.25% increase in net profit for 2025, with revenues reaching 294 million yuan [8] - 甬矽电子 achieved a 23.99% increase in net profit for 2025, with revenues of 4.4 billion yuan [9] - 三生国健 reported a remarkable 317.09% increase in net profit for 2025, with revenues of 4.199 billion yuan [10] - 中微半导's net profit grew by 108.05% in 2025, with revenues of 1.122 billion yuan [11] - 交控科技's net profit increased by 86.13% for 2025, with revenues of 2.537 billion yuan [12] Group 11: Corporate Name Change Announcement - 内蒙华电 has announced a change in its stock name to "华能蒙电" to enhance brand recognition [13] Group 12: Acquisition and Stock Suspension - 多瑞医药's stock will be suspended following the expiration of a tender offer for 19.44 million shares at 32.07 yuan each [14] - 东阳光 is planning to acquire control of 东数一号, leading to a temporary suspension of its stock [15] Group 13: Market Performance Overview - The Shanghai Composite Index rose by 0.87% on the first trading day of the Year of the Horse, with over 4,000 stocks increasing in value [16] - The oil and gas sector saw collective gains, with several stocks hitting the daily limit [16]

2月24日，市场冲高回落，创业板指盘中一度涨超2%，沪指放量收涨0.87%。在此背景下，红利低波 ETF华泰柏瑞（512890）全天上涨0.43%，报收1.172元，换手率1.72%，成交额5.15亿元，居同类ETF首 位。 | 代码 | 名称 现价 涨跌幅 IOPV 溢折率 换手率 成交金额 = 5日涨跌幅 ( | | --- | --- | | 512890 | 红利低波ETF华泰柏 1.172 0.43% 1.1719 0.01% 1.72% 5.15亿 -0.76% | | 563020 | 红利低波ETF易方达 1.196 0.67% 1.1936 0.20% 2.16% 1.35亿 -0.58% | | 159547 | 红利低波ETF华夏 1.211 0.67% 1.2099 0.09% 8.36% 7332.62万 -0.66% | | 159525 红利低波ETF | 1.096 0.55% 1.0942 0.16% 9.17% 4063.64万 -0.63% | | 560150 | 红利低波ETF泰康 1.137 0.62% 1.1368 0.02% 0.48% 403.49万 -0.8 ...

Core Viewpoint - The A-share market is expected to focus on technology as the main theme for 2026, with attention also on consumer and dividend sectors as investment opportunities [1] Group 1: Investment Strategies and Themes - E Fund emphasizes the increasing value of dividend assets in a low-interest-rate environment, with dividend yields around 5% and a potential influx of funds into these assets in 2026 [1] - 华夏基金 suggests that concerns over tightening overseas liquidity may be overestimated, and long-term investors could find attractive entry points in sectors like AI, media, and lithium batteries [2] - 富国基金 predicts a "central oscillation upward" trend for the A-share market in 2026, driven by recovery opportunities in consumption and real estate [3] - 汇添富 identifies A-shares as the most promising asset for 2026, highlighting the clear trend in the AI industry and the potential for valuation increases [8] - 博时基金 recommends focusing on emerging industries, resource upgrades, and domestic demand recovery as key investment directions for 2026 [10] Group 2: Sector-Specific Insights - 国泰基金 notes a policy shift towards domestic demand, which is expected to enhance China's economic outlook and asset returns, suggesting a good time for mid-term adjustments in sectors like AI and power equipment [5] - 鹏华基金 highlights the wine sector's potential for valuation recovery in 2026, while also emphasizing the attractiveness of the tourism sector in Hong Kong stocks [6][7] - 景顺长城 focuses on the long-term structural benefits for the equity market, particularly in technology sectors like AI, semiconductors, and consumer electronics [9] - 银河基金 discusses the commercial viability of space solar power and the need for domestic companies to overcome challenges in reusable rocket technology [11] - 东方红 suggests that cyclical sectors have high potential but require supply-side adjustments, while advocating for a bottom-up approach to identify undervalued stocks [12]

创业板50ETF国泰（159375）跟踪的是创业板50指数（399673），单日涨跌幅限制达20%，该指数从创 业板市场中选取日均成交额较大的50只证券作为指数样本，以反映知名、市值大且流动性好的企业整体 表现。其成分股主要集中于电力设备及新能源、医药、计算机等高成长性行业，整体呈现出显著的高成 长风格与良好流动性。 （文章来源：每日经济新闻） 野村东方国际证券指出，在流动性改善带动市场情绪走强的背景下，投资者可以对一季度A股表现给予 更多期待。全球通胀及增长情形，以及地缘局势的日趋紧张将进一步驱动周期商品表现。考虑到"十五 五"规划出台，其中对安全韧性的描述（自主可控的投资加码）、新兴产业的商业化（商业航天卫星、 6G、低空机器人）和货币与财政政策的创新空间有望对A股形成积极影响。投资者或可同步增加对中美 两国自主可控题材的关注度，在中国资产中加大对军贸、创新药、AI基建、商业航天与6G基建、工控/ 办公/AI软件等题材的关注。 ...

近年来，生物科技产业全面步入高速成长期，已成为引领全球科技革命与产业变革的关键赛道，持续吸 引海内外资金加速布局。马年伊始，恒生生物科技ETF华泰柏瑞（认购代码：513933，交易代码： 513930）于2026年2月24日起正式发售，为投资者提供一键布局港股生物科技核心资产的便捷投资工 具。 聚焦产业创新龙头，重点覆盖创新药+CXO方向 从成分股业务构成来看，指数高度聚焦创新药与CXO两大核心方向，合计权重接近90%，创新属性突 出。与此同时，指数还覆盖了AI+医疗等前沿领域优质标的，在精准捕捉医药赛道创新核心环节的同 时，映射中国生物科技产业的整体发展趋势。 凭借较高的创新药+CXO含量及鲜明的科技创新属性，恒生生物科技指数在2025年以来港股医药板块行 情中表现突出。截至2026年2月6日，该指数累计涨幅达76.52%，不仅跑赢同期恒生指数（32.40%）， 也显著超越恒生医疗保健（67.97%）、港股通医疗（34.21%）及恒生港股通创新药指数（70.43%）等 其他港股医药类指数，充分彰显其投资价值与成长弹性。 值得关注的是，截至2026年2月6日，恒生生物科技指数市盈率（PE-TTM）为29.60 ...

专题：四大证券报精华 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2月24日（星期二），今日报刊头条主要内容精华如下： 中国证券报 商务部新闻发言人就美国最高法院公布关税诉讼案裁决结果答记者问 问：美东时间2月20日，美国最高法院公布关税诉讼案裁决结果，判定美国政府依据《国际紧急经济权 力法》对相关贸易伙伴加征的对等关税、芬太尼关税等相关关税违法。请问商务部对此有何评价？答： 我们注意到美国最高法院公布关税诉讼案裁决结果，正在对相关内容和影响进行全面评估。中方一贯反 对各种形式的单边加征关税措施，反复强调贸易战没有赢家，保护主义没有出路。美方对等关税、芬太 尼关税等单边措施既违反国际经贸规则，也违反美国内法，不符合各方利益。事实反复证明，中美双方 合则两利，斗则俱伤。中方敦促美方取消对贸易伙伴加征的有关单边关税措施。我们也注意到，美方正 在准备采取贸易调查等替代措施，以期维持对贸易伙伴加征的关税，中方将对此保持密切关注并坚定维 护中方利益。 A股开市！机构研判来了 今天，A股将迎来马年首个交易日。结合春节假期期间外围市场表现，业内机构对A股节后表现整体持 积极态度，主要指数胜率有 ...

今日关注 1、商务部新闻发言人23日表示，我们注意到美国最高法院公布关税诉讼案裁决结果，正在对相关内容 和影响进行全面评估。我们也注意到，美方正在准备采取贸易调查等替代措施，以期维持对贸易伙伴加 征的关税，中方将对此保持密切关注并坚定维护中方利益。 1、据央视新闻，针对美国国务卿鲁比奥宣布任命新任美国"西藏特别事务协调员"一事，外交部发言人 表示，西藏事务是中国内政，美方此举是在干涉中国内政，中方从来不予承认。 2、23日，全社会跨区域人员流动量预计超3.6亿人次，比2025年同期增长11.9%，全国多地迎返程客流 高峰。 2、2026年中国电影票房（含预售）已突破80亿元，其中，春节档票房超57亿元。目前中国电影票房以 超北美市场近10亿元人民币的成绩领跑全球电影市场。 3、据中国国家铁路集团有限公司消息，23日正月初七是春节假期最后一天，全国铁路迎来返程客流最 高峰，预计发送旅客1850万人次，计划加开旅客列车2297列。 4、25日起，纳税人可以通过个人所得税App提前预约办理2025年度个人所得税综合所得汇算清缴。 2025年度个人所得税综合所得汇算清缴办理时间为2026年3月1日至6月30日。 5、 ...

Core Viewpoint - The A-share pharmaceutical and biotechnology industry has over 500 listed companies, with approximately 274 having disclosed their 2025 performance forecasts, indicating a generally positive outlook for the sector [1]. Group 1: Performance Forecasts - Among the 274 companies that disclosed forecasts, 90 companies are expected to have positive performance, including profit increases, slight increases, turnaround from losses, and continued profitability [1]. - 137 companies are projected to be profitable in 2025, representing 50% of those that disclosed forecasts, with 10 companies expected to achieve a net profit exceeding 1 billion yuan [1]. Group 2: Companies with Significant Profit Forecasts - The companies expected to report net profits exceeding 1 billion yuan include WuXi AppTec, 3SBio, and Jilin Aodong, all of which forecast profit increases [4][5]. - WuXi AppTec anticipates a revenue of approximately 45.456 billion yuan for 2025, a year-on-year increase of about 15.84%, with an adjusted net profit forecast of 14.957 billion yuan, reflecting a growth of approximately 41.33% [7]. - 3SBio expects a revenue of around 4.2 billion yuan, a significant increase of approximately 251.76%, and a net profit of about 2.9 billion yuan, marking a growth of approximately 311.35% due to a key collaboration with Pfizer [9]. Group 3: Companies with Loss Forecasts - A total of 137 companies are expected to report losses in 2025, with the top three companies projected to incur losses exceeding 1 billion yuan each, including Zhifei Biological Products, Zhenbao Island, and Baile Tianheng [11]. - Zhifei Biological Products forecasts a net loss between 10.698 billion yuan and 13.726 billion yuan, primarily due to underperformance in sales and inventory impairment [15]. - Zhenbao Island anticipates a net loss of 1.012 billion yuan to 1.173 billion yuan, impacted by policy adjustments and increased cost control measures in the pharmaceutical industry [15].

（原标题：美股前瞻 | 三大股指期货齐跌 特朗普关税不确定性席卷市场） 1. 2月23日(周一)美股盘前，美股三大股指期货齐跌。截至发稿，纳指期货现跌0.66%，标普500指数期 货跌0.46%，道指期货跌0.49%。 被美国最高法院裁定"非法"的关税完结在即! 15%全球新税无缝接棒。美国海关与边境保护局(CBP)表 示，将于周二美国东部时间凌晨12:01停止征收依据《国际紧急经济权力法》(IEEPA)实施的美国政府对 等关税举措——此举距美国最高法院宣告这些关税为"非法"性质征收已过去三天多。该政府机构在其货 物系统消息服务(CSMS)向托运人发布的消息中称，将自美东时间周二起停用与美国总统特朗普此前 IEEPA相关行政命令有关的所有关税政策代码。尽管在最高法院关税裁决公布之后，美国总统特朗普告 诉记者，美国政府不久后将在《1974年贸易法》第122条款下对全球征收15%的关税，但尚不清楚美国 政府是否需要退还已经征收的关税款项。 存储芯片巨头SK海力士：将扩大AI存储芯片产能以应对需求激增。在股价过去一年飙升逾四倍、创下 盈利纪录之际，SK海力士母公司SK集团董事长崔泰源承诺将显著扩大AI存储芯片产能， ...